Introduction
Tuberculosis (TB) continues to be a major health problem throughout the world. About 2 billion (one third of the world's population) people are infected with TB of which about 10% develop clinical disease. [1] The most common form of TB is pulmonary, and the most dangerous is CNS tuberculosis accounting for 5.2% of clinical TB and almost 50% morbidity. [2] and often leads to worse prognosis. [10] Reliable independent prognosticators in TBM are extremes of age and advanced disease at presentation. [11] Mortality of treated cases is 10% to 30%. [11] The risk of neurological impairment despite treatment is also a direct correlate of stage of illness at presentation. Neurologic disabilities ranging from mild to severe are reported in 10% to 50% of both adults and children who survived the infection. [12] Complications of CNS tuberculosis, such as shunting procedures for the treatment of hydrocephalus. When the diagnosis is not ensured and there is no response to therapy within 8 weeks, a stereotactic biopsy on a suspected tuberculoma could be performed. If the largest lesion is not located in high risk deep regions of the brain, it could be totally removed surgically. With this combined management, a satisfactory outcome can be obtained in the majority of cases. [13] 
Materials and Methods

Methods
This study was conducted in the Department of Neurosurgery and Neurology Skims Srinagar India for a period of two years from November 2009 to November 2011. A total of 61 patients presenting with brain tuberculosis admitted at skims during these two years were included in the study.
The patients were subjected to thoroughClinical examination: To establish a diagnosis of tuberculosis of brain.
Clinical-laboratory tests
Complete hemogram, ESR, chest x-ray, Montaux test were done. CSF of these patients was subjected to detailed cytology, biochemistry ADA and PCR analysis. CSF was also taken for ZN staining and culture.
History: Of contact with a known patient of pulmonary tuberculosis, history of recent or past intake of ATT was also taken. The diagnosis of brain tuberculosis was based on the following parameters:-• Clinical symptoms-headache, vomiting, fever, and signs of meningisms of more than 4 weeks duration The patients selected were classified into three stages according to clinical features and three types according to CT findings. 
Clinical staging
Radiological staging
On the basis of CT scan findings patients were divided in to three grades: Grade I: Isolated meningeal involvement Grade II: Isolated parenchymal involvement Grade III: Compound parenchymal and meningeal involvementningeal.
Medical or Combined Surgical and Medical
The patients were put on medical or combined surgical and medical treatment and followed for a period of 18 months and were assessed serially for demonstration of clinical and radiographic resolution with or without radiographic sequelae or with radiographic sequelae like atrophy/calcification with persistent enhancement.
Medical treatment
Was started with 4 drugs daily, that is, isoniazid 5 mg/kg (maximum 300 mg, rifampicin 10 mg/kg, pyrazinamide 25 mg/kg, and ethombutol 20 mg/kg or streptomycin 20 mg/kg (maximum 1 g) for 2 months and isoniazid and rifampicin daily for 4 to 24 months depending upon the response. The response to treatment was determined by clinical improvement or in some byrepeat CSF analysis; six monthly CT-scan in those with tuberculomas or other findings at the start of treatment. The patients with tuberculomas needed prolonged treatment. Steroids were added for first 4 weeks and tapered over a similar period in clinical stage II and III disease.
Surgical treatment
Was done in the form of ventriculoperitoneal shunt for hydrocephalus and excision of tuberculomas with considerable mass effect.
Results
Age of the studied patients
The total number of study subjects were 61 with age range of 1-65 years with a mean age of 30.85 ± 16.91 years; 27 of 61 (44.3%) were males and 34 (55.7%) were females. Six of the patients were below 10 years of age and most were 11-40 years. There was a higher incidence of tubercular meningitis in younger (<40 years) age group (P < 0.05). The most presenting symptom of the study subjects was headache found in 95.10% followed by vomiting found in 86.90% of subjects, fever in 78.70% CONSCIOUS LEVEL in 49.20%, seizures in 19.70% and diplopia in 18%.
Clinical characteristics in studied subjects
In our study of 61 patients of brain tuberculosis on clinical examination cranial nerve involment was found in 34 (55.73%) 
CT stage at presentation in studied subjects
CT scan of head was abnormal in 56 of 61 patients (91.8%). on admission. The study subjects were divided into three stages on the basis of CT scan finding at the time presentation and out of total 56 subjects 12 (19.70%) were in stage I (meningeal involvement only), 29 (47.50%) were in stage II (parenchymal involvement only) and 15 (24.60%) werein stage III (both parenchymal and meningeal involvement). The most common finding in CT head was meningeal enhancement in 43 patients, hydrocephalus in 37 patients and tuberculomas in 14 patients. The most common sites of tuberculomas were frontal lobe (n = 6; 42.8%), parietal lobe (n = 4; 28.5%), followed by cerebellum in 2 patients and occipital in two.
Nine patients had single and five multiple tuberculomas. Of the 14 patients with tuberculomas, hydrocephalus on CT was seen in 6 patients. 
Clinical stage of meningitis across mortality
Five of our subjects died during the hospital stay within 4 weeks of presentation and no mortality was seen on follow up. Out of the five patients who died three were in clinical stage III at presentation. Maximum mortality was seen in stage III meningitis (60%). A statistically significant association mortality was observed with higher clinical stage (III) at presentation (P =0.013). All the patients who died underwent VP shunting. Two of the three patients in stage III who died had severe obstructive hydrocephalus with a GCS of <6/15 and died in post-operative period due to sepsis because of aspiration pneumonia. One patient in stage III, a 6 year old boy, died ofbrainstem compression by tuberculoma. The mortality seen in stage I was an elderly male with underlying type 2 diabetes with hypertensive cardiovascular disease and chronicobstructive air way disease (COAD), developed hospital acquired pneumonia and died of a massive pulmonary thromboembolism. The patient who died in stage II disease presented with status epilepticus with anoxic brain injury and died of a sudden cardiac arrest in the ward.
Modalities of treatment in our patients
Thirty one patients in our study received medical and 30 patients combined medical and surgical treatment. Of the five patients who died one was on medical and four combined medical and surgical management. All the patients received four antitubercular drugs (H = isoniazid; R = rifampicin; Z = pyrazinamide; E = ethambutol) for a period of three months followed by isoniazid and rifampicin for 15 months. Steroids were given to all patients in stage III and most of the patients in stage II. Only one patient deteriorated during initial six weeks of medical management with increase in size and number of tuberculomas. Thirty patients needed surgical intervention; VP shunts in 26 (11 patients had mild hydrocephalus who didn't need shunt) and excision of tuberculomas in 4 patients. Of the 26 shunted patients, 18 were shunted during the first 4 weeks of admission whereas in 6 patients shunting was done in initial 6 months of follow up in view of development oh hydrocephalus and worsening of clinical stage on medical management only. Excision of tuberculomas in all the four patients was done in initial 4 weeks. The indication of excision in three patients was the mass effect produced by tuberculomas leading to drop in GCS and worsening of clinical stage. In all these patients the size of tuberculoma exceeded four cms. The average size of tuberculomas which were managed conservatively was 2.8 mms. The most common sites of excision of tuberculomas were from frontal and parietal lobe. In one patient excision was done as a part of diagnostic procedure with an initial impression of meningioma and histopathology proved it to be a tuberculoma. This was one of the eight patients who presented with tuberculomas only with no evidence of meningitis.
Serial clinical and CT findings on follow up
Of the 61 patients included in the study, 56 were followed for a period ranging from 6 months to 18 months with a mean follow up period of 12 months. At 6 month follow the mean GCS of the patients improved from 10.7 at admission to 13. On correlating the worst CT characteristics-tuberculomas, basal exudates and hydrocephalus with sequelae at 6 months -focal deficit, cognitive impairment, and diplopia it was seen that basal exudates correlated with all the three neurological sequelae i.e.; with focal deficit (P = 0.001), cognitive impairment (P = 0.011), and diplopia (P = 0.021). Hydrocephalus correlated well with cognitive impairment (P = 0.031) and tuberculoma correlated with none of these clinical characteristics.
Discussion
Tubercular meningitis is common in developing countries, with a high morbidity and mortality. The diagnosis of TBM is based mainly on clinical and laboratory findings, particularly in adults. [14] Tubercular meningitis in developing countries is more common in infants and children with an increasing incidence in adolescents and young adults. In populations with low prevalence of TB, most cases of TBM occur in adults, and HIV has definitely increased the risk in adults.
In our study of 61 patients of brain tuberculosis on 32.80% patients were in clinical stage I, 59.00% were in clinical stage II and 8.2% were in clinical III of meningitis. Sixty seven percent of the patients presented with severe disease (stages II and III). Five patients were deeply comatose on admission with a GCS of <6/15. Similar findings have been reported by Abdul Majid et al. [15] wherein about 89.47%of the patients presented with severe disease, that is, stage II (50%) and stage III (39.47%). Our results were also matching with Mishra et al. [16] where 83% of patients presented with severe disease.
Computed axial tomographic scanning with contrast and magnetic resonance imaging have brought most of the intracranial pathology visible to the naked eye [9] Abnormalities reported on CT scan done in stages II and III disease are hydrocephalus, infarcts, basal enhancement, and cerebral edema. [10] Normal study is reported in up to 20% of the cases. Abdul Majid et al. [15] reported abnormal CT findings in 73.52% patients as basal enhancement in 36%, hydrocephalus in 28%, tuberculomas in 52%, infarcts in 12.0%, cerebral edema in 8.0%, and more than 1 finding in 32.0% of the patients. Normal study was in 26.4%. All patients in stage I disease had abnormal CT findings in comparison to 50% of stage II and 83.3% of stage III disease. Thus, CT scan is a useful diagnostic tool even in very early stages of TBM. Hydrocephalus frequently accompanies tuberculous meningitis. The hydrocephalus is probably a result of basal adhesive meningeal reaction wherein the flow of the CSF is obliterated in its course from the point of exit from the fourth ventricle to the site of its absorption in the arachnoid villi. The intraventricular pressure in cases of hydrocephalus with tuberculous meningitis is generally low or only marginally raised. [17] CT scan of head was normal in 5 of 61 patients (9%) of our subjects on admission. The study subjects were divided into three stages on the basis of CT scan finding at the time presentation and out of total 56 subjects 19.70% were in CT stage I, 47.50% were in stage II and 24.60% were in stage III (depending upon the involvement of meninges, parenchyma or both). The most common finding in CT head was meningeal enhancement in 76% of patients, hydrocephalous in 66% patients and tuberculomas in 25% patients. There was no correlation of higher clinical stage at presentation with higher CT stage (P = 0.627). Ninety fivepercent (95%) of patients (19 of 20) in clinical stage I had abnormal CT scan in comparison to 88% of stage II. All the patients in stage III had abnormal CT. CT scan is a better diagnostic modality even in stage I of the disease.
Despite the introduction of new and potent anti-tuberculous drugs, the mortality and morbidity in patients with CNS tuberculosis remains exceptionally high. The mortality and sequelae are directly related to the stage of the disease at the time of initiation of appropriate therapy. The treatment strategy for tuberculous meningitis and hydrocephalus should be aggressive anti-tuberculous drugs and wherever necessary institution of steroids. Ventricular CSF diversionary surgery may not be necessary in most cases and can be avoided. Shunt surgery on the basis of radiological imaging diagnosis and for the sake of helping the situation of hydrocephalus in presence of other florid evidence of tuberculous meningitis, more often than not, is of no benefit. Monitoring of intraventricular pressure can be helpfulin situations where there is doubt about the need of a shunt operation. Due to an immunocompromised state of patients with tuberculous meningitis, chances of shunt tube related infection are more predominant. In adolescents and adults with tuberculous meningitis and hydrocephalus, the signs of increased intracranial pressure and drowsiness are more predominant. Such patients are usually benefited by a shunt. In some cases, when the disease process is dying
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Jacobs and others [18] and Kent and others [19] found that the mortality in patients admitted in stage III was approximately 50% while for those in stages II and I it was 30% and 15%, respectively. Five of our subjects died during the hospital stay and no mortality was seen on follow up. Out of the five patients who died three had stage III disease at presentation (60%). Maximum mortality was seen in stage III. The mortality and neurologic sequelae were directly related to the stage of disease on admission (P = 0.013). Girgis NI, et al. [20] also reported similar results in their study with 72% mortality in stage III disease. Similarly, the number of patients who recovered completely without any sequelae was significantly higher (P, 0.03) in patients admitted in stage I (15 of 19; 78%) compared with those in stages II (13 of 35; 37%). At 18 months follow up 60% of the patients attained full recovery and 40% were left with some functional impairment (29% of the patients were left with permanent sequelae). This is much lower than the 53% observed by Idriss [21] and others.
In our study nine patients deteriorated during the initial six weeks of treatment. A number of clinical and radiological phenomena in TBM may be due to ongoing infection or inflammation which could result in continued deterioration. The initial deterioration in TBM could be due to an immunoallergic reaction resulting in liberation of cytokines and lymphokines and subsequent appearance or organization of basal exudates, termed a ''paradoxical response''. This is an uncommon hypersensitivity reaction to massive release of tuberculo protein into the subarachnoid space, manifest clinically within days of commencement of treatment; the patient may rapidly deteriorate to coma or even death. [19] This therapeutic paradox has been regarded as pathognomonic of TBM. [22] The initial deterioration in at least three of our patients could be due to a paradoxical response.
Within 6 months, however, most of our patients, including those who deteriorated initially either becames or started improving. Radiological follow up revealed new hydrocephalus in 6 patients which could be due to organization of basal exudates, in these patients. At 6 months no patient worsened clinically or radiologically but 51 of 56 CT studies remained abnormal. In one serial study of CT and MRI in TBM all abnormal CT findings except infarcts disappeared. [23] This difference from our study could be attributed to milder illness and use of MRI in the previous study. More severe illness in our patients is evidenced by stage II and III meningitis in 67.2% and hydrocephalus in 60%. In a clinical and CT follow-up of 25 patients with TBM, 18 had hydrocephalus on admission and hydrocephalus developed in three during follow-up. In seven patients exudates persisted for 11-96 months. New tuberculomas appeared even after 7 months of treatment in our study however exudates resolved in all the patients at 18 months. It can be concluded that close monitoring of patients with TBM during the first 6 weeks of treatment is essential as 14% of patients may deteriorate, especially those with low GCS and weakness. Repeating CT can be valuable in their management. Most CT abnormalities persist even after 6 months despite clinical improvement.
On correlating the worst CT characteristics-tuberculomas, basal exudates and hydrocephalous with sequelae at 6 months -focal deficit, cognitive impairment, and diplopia it was seen that basal exudates correlated with all the three sequelae ie.; with focal deficit (P = 0.001), cognitive impairment (P = 0.011), and diplopia (P = 0.021). Hydrocephalous correlated well with cognitive impairment (P = 0.031) and tuberculoma correlated with none of these clinical characteristics. P Ranjan [24] correlated the worst CT appearances with 6-month clinical sequelae and found that motor deficit correlated with exudates (P < 0.05) and infarcts (P < 0.05). Hydrocephalous and tuberculoma did not correlate with sequelae. Correlating the 6-month CT findings with neurological sequelae at 6 months, cognitive impairment correlated with exudates (P < 0.05) and tuberculomas (P < 0.05). Functional outcome at 6 months was related to the presence of exudates at 6 months (P < 0.05).
